Form 8-K - Current report:
SEC Accession No. 0001193125-24-265244
Filing Date
2024-11-25
Accepted
2024-11-25 17:05:52
Documents
13
Period of Report
2024-11-25
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d851139d8k.htm   iXBRL 8-K 24960
  Complete submission text file 0001193125-24-265244.txt   150713

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vinc-20241125.xsd EX-101.SCH 2839
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20241125_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20241125_pre.xml EX-101.PRE 11700
15 EXTRACTED XBRL INSTANCE DOCUMENT d851139d8k_htm.xml XML 3767
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

EIN.: 833197402 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39244 | Film No.: 241496899
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)